Abstract
Prostate cancer is the most common cancer for man with a high mortality rate due to a lack of non-invasive accurate and sensitive molecular diagnostic methods. The molecular imaging of cancer biomarkers using MRI with its spatial and temporal resolution, however, is largely limited by the lack of contrast agents with high sensitivity, targeting specificity and deep tumor penetration. In this review, we will first overview the current stage of prostate cancer diagnosis and then review prostate cancer biomarkers and related imaging techniques. Since biomarker targeting moieties are essential for molecular imaging, we will use prostate-specific membrane antigen (PSMA) as an example to discuss different methods to characterize the interaction between biomarker and targeting moieties. At the end, we will review current progress of the development of targeted protein-based MRI contrast agents (ProCAs) for prostate cancer biomarkers with improved relaxivity and targeting capability.
Keywords: Molecular imaging, protein-based MRI contrast agents, GRPR, PSMA, biomarkers.
Current Protein & Peptide Science
Title:Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents
Volume: 17 Issue: 6
Author(s): Fan Pu, Shenghui Xue, Jingjuan Qiao, Anvi Patel and Jenny J. Yang
Affiliation:
Keywords: Molecular imaging, protein-based MRI contrast agents, GRPR, PSMA, biomarkers.
Abstract: Prostate cancer is the most common cancer for man with a high mortality rate due to a lack of non-invasive accurate and sensitive molecular diagnostic methods. The molecular imaging of cancer biomarkers using MRI with its spatial and temporal resolution, however, is largely limited by the lack of contrast agents with high sensitivity, targeting specificity and deep tumor penetration. In this review, we will first overview the current stage of prostate cancer diagnosis and then review prostate cancer biomarkers and related imaging techniques. Since biomarker targeting moieties are essential for molecular imaging, we will use prostate-specific membrane antigen (PSMA) as an example to discuss different methods to characterize the interaction between biomarker and targeting moieties. At the end, we will review current progress of the development of targeted protein-based MRI contrast agents (ProCAs) for prostate cancer biomarkers with improved relaxivity and targeting capability.
Export Options
About this article
Cite this article as:
Pu Fan, Xue Shenghui, Qiao Jingjuan, Patel Anvi and Yang J. Jenny, Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents, Current Protein & Peptide Science 2016; 17 (6) . https://dx.doi.org/10.2174/1389203717666160101123725
DOI https://dx.doi.org/10.2174/1389203717666160101123725 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protease Inhibitors in the Clinic
Medicinal Chemistry Inhibition of Tumor Cell Invasiveness by Chemically Modified Tetracyclines
Current Medicinal Chemistry Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer
Current Gene Therapy Editorial (End of the Beginning and Public Health Pharmacogenomics: Knowledge in ‘Mode 2’ and P5 Medicine)
Current Pharmacogenomics and Personalized Medicine Circulating Levels of Angiogenic Cytokines in Waldenstrom’s Macroglobulinemia: Clinical Correlations
Current Angiogenesis (Discontinued) Editorial [Hot Topic: Therapeutic Application of Melanocortin-4 Receptor Ligands (Guest Editor: John P. Mayer)]
Current Topics in Medicinal Chemistry Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) BTX AgilePulse<sup>TM</sup> System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine
Current Gene Therapy 3D-QSAR (CoMFA, CoMSIA) and Molecular Docking Studies on Histone Deacetylase 1 Selective Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Curcumin and Liver Cancer: A Review
Current Pharmaceutical Biotechnology Telomerase Inhibitors: Potential Anticancer Agents
Mini-Reviews in Organic Chemistry Cannabinoids and Myocardial Ischemia: Novel insights, Updated Mechanisms, and Implications for Myocardial Infarction
Current Medicinal Chemistry Understanding and Targeting Osteoclastic Activity in Prostate Cancer Bone Metastases
Current Molecular Medicine Influence of Leptin on Immunity
Current Immunology Reviews (Discontinued) Meet Our Editorial Board Member
Current Medicinal Chemistry Role of Progesterone in Human Astrocytomas Growth
Current Topics in Medicinal Chemistry Wnt Signaling and Prostate Cancer
Current Drug Targets Current View on the Mechanism of Action of Perifosine in Cancer
Anti-Cancer Agents in Medicinal Chemistry